Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer Therapy
Open Access
- 1 January 2010
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 151 (1), 32-42
- https://doi.org/10.1210/en.2009-0855
Abstract
Aromatase, the enzyme that catalyzes estrogen synthesis, is critical for the progression of estrogen receptor-positive breast cancer (BCa) in postmenopausal women. We show that calcitriol, the hormonally active form of vitamin D, regulates the expression of aromatase in a tissue-selective manner. Calcitriol significantly decreased aromatase expression in human BCa cells and adipocytes and caused substantial increases in human osteosarcoma cells (a bone cell model exhibiting osteoblast phenotype in culture) and modest increases in ovarian cancer cells. Calcitriol administration to immunocompromised mice bearing human BCa xenografts decreased aromatase mRNA levels in the tumors and the surrounding mammary adipose tissue but did not alter ovarian aromatase expression. In BCa cells, calcitriol also reduced the levels of prostaglandins (PGs), major stimulators of aromatase transcription, by suppressing the expression of cyclooxygenase-2 (which catalyzes PG synthesis) and increasing that of 15-hydroxyprostaglandin dehydrogenase (which catalyzes PG degradation). The mechanism of aromatase down-regulation by calcitriol in BCa cells is therefore 2-fold: a direct repression of aromatase transcription via promoter II through the vitamin D-response elements identified in this promoter and an indirect suppression by reducing the levels of PGs. Combinations of calcitriol with three different aromatase inhibitors (AIs) caused enhanced inhibition of BCa cell growth. The combination of calcitriol and an AI may have potential benefits for BCa therapy. In addition to augmenting the ability of AIs to inhibit BCa growth, calcitriol acting as a selective aromatase modulator that increases aromatase expression in bone would reduce the estrogen deprivation in bone caused by the AIs, thus ameliorating the AI-induced side effect of osteoporosis.Keywords
This publication has 58 references indexed in Scilit:
- Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancerBreast Cancer Research and Treatment, 2009
- Elevated Aromatase Expression in Osteoblasts Leads to Increased Bone Mass Without Systemic Adverse EffectsJournal of Bone and Mineral Research, 2009
- Prostaglandin E2 Induces Breast Cancer–Related Aromatase Promoters via Activation of p38 and c-Jun NH2-Terminal Kinase in Adipose FibroblastsCancer Research, 2007
- Generation of Novel Adipocyte Monolayer Cultures from Embryonic Stem CellsStem Cells and Development, 2007
- Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulationActa Endocrinologica, 2005
- Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor YBiochemical and Biophysical Research Communications, 2005
- Suppression of the Human Parathyroid Hormone Promoter by Vitamin D Involves Displacement of NF-Y Binding to the Vitamin D Response ElementOnline Journal of Public Health Informatics, 2004
- Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expressionJournal of Cellular Biochemistry, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976